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A b s t r a c t
Introduction: There are inconsistent data on the sex-related differences in clinical outcomes and quality of life (QoL) after tran-
scatheter aortic valve implantation (TAVI).
Aim: We sought to investigate sex-related differences in procedural, clinical and QoL outcomes of TAVI.
Material and methods: A total of 101 consecutive patients undergoing TAVI were enrolled. Patients were stratified by gender. 
Baseline characteristics, procedural and long-term clinical outcomes as well as frailty and QoL indices (EQ-5D-3L questionnaire) 
were compared between women and men.
Results: Women represented 60.4% of the study population. Periprocedural risk measured with the Logistic EuroSCORE and 
STS scale was similar for women and men. There were no differences in 30-day or 12-month all-cause mortality between groups 
(women vs. men: 9.8% vs. 12.5%; age-adjusted odds ratio (OR) (95% CI): 1.38 (0.39–4.94); 13.1% vs. 25.0%; age-adjusted OR 
(95% CI): 2.51 (0.87–7.25)). Men were at higher risk of new onset atrial fibrillation at follow-up (1.6% vs. 17.5%; age-adjusted OR 
(95% CI): 14.61 (1.68–127.37)). In multivariable Cox regression analysis, a history of stroke/transient ischemic attack (TIA) (hazard 
ratio (HR)) (95% CI): 3.93 (1.39–11.07) and blood transfusion (HR (95% CI): 2.84 (1.06–7.63)) were identified as independent factors 
affecting 12-month mortality. No differences in QoL parameters were noted.
Conclusions: The TAVI can be considered as an effective and safe treatment in high-risk patients with severe aortic stenosis, 
regardless of gender.
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Introduction
Transcatheter aortic valve implantation (TAVI) is an ef-
fective alternative to conventional surgical treatment of 
severe aortic stenosis (AS) in high-risk patients, providing 
good clinical outcomes [1–4] and improvement in quality 
of life (QoL) in long-term follow-up [5–7]. Previous reports 
were inconsistent in terms of the gender-related differ-
ences in clinical outcomes after TAVI [8–16]. Importantly, 
female gender is considered as a  risk factor for cardiac 
operations in both the Society of Thoracic Surgeons (STS) 
Predicted Risk of Mortality Score and in the Logistic Euro-
SCORE [8]. Most of the recent studies and meta-analyses 
have reported the protective effect of female gender in pa-
tients undergoing TAVI [8, 9, 12, 14, 16]. In contrast, wom-
en appear to experience more often postprocedural com 
plications with major vascular complications, major and 
life-threatening bleeding and blood transfusions [8, 9, 12, 
14, 16]. Despite the growing body of evidence in favor of 
female gender and widespread use of TAVI, there are still 
limited and inconsistent data on the influence of gender 
on procedural results as well as clinical and QoL outcomes. 
Aim
We sought to investigate sex-related differences in 
procedural, clinical and QoL outcomes of TAVI.
Material and methods
A total of 101 consecutive patients who underwent 
TAVI at our center were included. All patients were diag-
nosed with symptomatic severe AS and had high surgi-
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cal risk or contraindications for aortic valve replacement 
(AVR). Patients were clinically evaluated to assess op-
erative risk, comorbidities, frailty, and procedural feasi-
bility. Baseline characteristics and procedural data were 
prospectively collected. The frailty index was assessed 
before TAVI with the Katz index of Independence of Ac-
tivities in Daily Living (KI), elderly mobility scale score 
(EMS), Canadian Study of Health and Aging (CSHA) 
scale, 5-meter walking test (5MWT), dominant hand grip 
strength, and Identification of Seniors at Risk (ISAR) scale 
[17]. To assess hand grip strength patients were asked 
to squeeze the dominant hand as tightly as possible (re-
peated twice). The results were distinguished as follows: 
weak, mild, and strong. Patient screening and selection 
were performed by a multidisciplinary Heart Team sup-
ported by clinical and imaging resources. The TAVI pro-
cedures were performed using Edwards Sapien, Edwards 
Sapien XT, Edwards Sapien 3 (Edwards Lifesciences), 
Medtronic CoreValve (Medtronic, Inc), and JenaValve (Je-
naValve Technology). Access routes were transfemoral, 
transapical and direct aortic. Procedures were performed 
under general anesthesia or local anesthesia with seda-
tion. Clinical endpoints of the study included all-cause 
mortality at 30 days and 12 months. The QoL was as-
sessed with the validated Polish version of the EQ-5D-3L 
questionnaire at baseline and at 12 months after TAVI. 
The visual analog scale (VAS) score, which is a  part of 
the EQ-5D-3L, was also assessed. All endpoints were as-
sessed according to the recommendations of the Valve 
Academic Research Consortium (VARC-2) [18]. For the 
purpose of this analysis, patients were divided into two 
groups according to gender. The study was approved by 
the institutional ethical board.
Statistical analysis
Results are presented as number of patients (per-
centages) or median (interquartile range (IQR)) where 
applicable. Differences between groups were tested us-
ing the c2 test and Fisher’s exact test for dichotomous 
variables and the Mann-Whitney U-test for continuous 
variables. Changes in the proportions of patients who 
reported either “no problems” or “some problems”/“ex-
treme problems” on the EQ-5D-3L between baseline and 
follow-up visits were analyzed using McNemar’s test. 
Differences in the VAS score between baseline and fol-
low-up assessments were analyzed with the Wilcoxon 
signed-rank test. All paired comparisons between base-
line and 12-month measurements were performed ex-
cluding unpaired results. The difference in mortality be-
tween men and women during follow-up was assessed 
by the Kaplan-Meier method. In addition, differences in 
outcomes were presented as age-adjusted odds ratios 
(OR) with 95% confidence intervals (CI). In addition, mul-
tivariable Cox regression analysis was performed to find 
significant predictors of 12-month mortality. All baseline 
characteristics and procedural data were tested. Forward 
selection with a probability value for covariates to enter 
the model was set at the 0.05 level. Results were pre-
sented as hazard ratios (HR) with 95% CI. All tests were 
two-tailed, and a p-value of < 0.05 was considered statis-
tically significant. All statistical analyses were performed 
using SPSS 15.0 (SPSS, Inc).
Results
Of the 101 consecutive patients undergoing TAVI 
women represented 60.4% of the study population. 
Baseline clinical and demographic characteristics are pre-
sented in Table I. Women were more often over 80 years 
old, with a  lower rate of previous myocardial infarction 
(age-adjusted OR = 6.34, 95% CI: 2.44–16.46; p = 0.001), 
previous coronary artery bypass grafting (age-adjusted 
OR = 3.32, 95% CI: 1.11–9.96; p = 0.03) and incomplete 
revascularization (age-adjusted OR = 3.30, 95% CI: 1.07–
10.19; p = 0.04) than men (Table I). In addition, a high-
er prevalence of atrial fibrillation (AF) among women 
than men was noted. However, this difference was not 
significant after adjustment for age (age-adjusted OR = 
0.44, 95% CI: 0.17–1.09; p = 0.08). Importantly, no dif-
ferences in periprocedural risk measured with Logistic 
EuroSCORE and STS were noted. Procedural details are 
shown in Table II. Similar length of hospital stay was 
observed for women and men (10.0 (7.0–12.0) vs. 13.0 
(6.5–19.5) days; p = 0.45). Also, no differences in frailty 
features were observed (Table III). QoL parameters as-
sessed with the EQ-5D-3L questionnaire are presented 
in Figure 1. Lower rates of problems with usual activities 
in men than women at 12 months were noted. However, 
these results were not maintained after adjustment for 
gender (age-adjusted OR = 0.28, 95% CI: 0.07–1.08; p = 
0.07). The median visual analog scale (VAS) at baseline 
(women vs. men: 40.0 (35.0–50.0) vs. 40.0 (35.0–50.0); 
p = 0.92) and 12 months after TAVI (70.0 (60.0–75.0) vs. 
70.0 (62.5–80.0); p = 0.15) were comparable between 
groups. There were no differences in VAS change during 
follow-up in both female and male patients (25.0 (15.0–
30.0) vs. 21.0 (15.0–40.0); p = 0.83, respectively). There 
were no differences in 30-day and 12-month all-cause mor-
tality between groups (women vs. men: 9.8% vs. 12.5%; 
p = 0.75 and 13.1% vs. 25.0%; p = 0.13) – Figure 2. Also, 
no influence of gender on the risk of mortality was con-
firmed after adjustment for age (for 30-day age-adjusted 
OR = 1.38, 95% CI: 0.39–4.94; for 12-month age-adjusted 
OR = 2.51, 95% CI: 0.87–7.25). Rates of in-hospital acute 
kidney injury (2.7% vs. 10.5%; p = 0.18; age-adjusted 
OR = 1.25, 95% CI: 0.19–8.13), bleeding complications 
(27.9% vs. 35.0%; p = 0.45; age-adjusted OR = 1.49, 95% 
CI: 0.62–3.56) and blood transfusions (26.2% vs. 30.0%; 
p = 0.68; age-adjusted OR = 1.30, 95% CI: 0.53–3.20) 
were comparable between groups. Similarly, no differenc-
es in stroke/TIA (3.3% vs. 15.0%; p = 0.06; age-adjusted 
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OR = 5.12, 95% CI: 0.97–27.06), myocardial infarction 
(1.6% vs. 7.5%; p = 0.30; age-adjusted OR = 4.48, 95% CI: 
0.44–45.27) or need for permanent pacemaker stimula-
tion (16.4% vs. 15.0%; p = 0.85; age-adjusted OR = 0.86, 
95% CI: 0.28–2.62) were reported during 12-month 
follow-up. Interestingly, new-onset AF was observed 
more often after TAVI in male patients (1.6% vs. 17.5%; 
p = 0.006). However, this difference was no longer signif-
icant after adjustment for age (age-adjusted OR = 14.61, 
95% CI: 1.68–127.37), which may suggest that the differ-
ence in new-onset AF was driven mainly by the difference 
in age between groups rather than gender per se. Gender 
was not identified as an independent predictor of mor-
tality in multivariable Cox regression analysis. A history 
of stroke/TIA (HR = 3.93, 95% CI: 1.39–11.07; p = 0.001) 
and blood transfusion (HR = 2.84, 95% CI: 1.06–7.63; 
p = 0.04) were identified as independent factors affect-
ing 12-month mortality.
Discussion
Our study revealed no differences in crude and age-ad-
justed 30-day and 12-month all-cause mortality rate be-
tween women and men with severe AS undergoing TAVI. 
Also, the only independent predictors of 12-month mor-
tality in our cohort were previous stroke/TIA and blood 
transfusion. In the study we outlined the frailty and QoL 
Table I. Baseline clinical and echocardiographic characteristics
Parameter All patients (n = 101) Women (n = 61) Men (n = 40) P-value
Age, median (IQR) [years] 81.0 (76.0–84.0) 82.0 (78.0–84.0) 79.0 (73.0–83.0) 0.10
Age ≥ 80 years, n (%) 59 (58.4) 41 (67.2) 18 (45.0) 0.027
Body mass index, median (IQR) [kg/m2] 28.0 (25.2–31.1) 28.7 (25.4–32.0) 27.3 (25.4–28.7) 0.15
eGFR, median (IQR) [ml/min/1.73 m2] 61.0 (39.0–81.0) 60.5 (39.5–77.0) 65.0 (43.0–73.0) 0.80
NYHA class, n (%): 0.36
I 0 (0.0) 0 (0.0) 0 (0.0)
II 17 (16.8) 9 (14.8) 8 (20.0)
III 74 (73.3) 44 (72.1) 30 (75.0)
IV 10 (9.9) 8 (13.1) 2 (5.0)
Arterial hypertension, n (%) 94 (93.1) 56 (91.8) 38 (95.0) 0.70
Diabetes mellitus, n (%) 35 (34.7) 22 (36.1) 13 (32.5) 0.71
Atrial fibrillation, n (%) 35 (34.7) 26 (42.6) 9 (22.5) 0.038
History of myocardial infarction, n (%) 31 (30.7) 10 (16.4) 21 (52.5) < 0.001
PCI, n (%) 29 (28.7) 16 (26.2) 13 (32.5) 0.50
CABG, n (%) 17 (16.8) 6 (9.8) 11 (27.5) 0.020
CTO, n (%) 9 (8.9) 3 (4.9) 6 (15.0) 0.15
Incomplete revascularization, n (%) 16 (15.8) 6 (9.8) 10 (25.0) 0.041
COPD, n (%) 9 (8.9) 3 (4.9) 6 (15.0) 0.21
Stroke/TIA, n (%) 10 (9.9) 6 (9.8) 4 (10.0) 0.99
Pacemaker, n (%) 11 (11.1) 6 (9.8) 5 (13.2) 0.75
Logistic EuroSCORE I, median (IQR) [%] 14.0 (10.0–22.5) 12.5 (8.5–22.0) 15.0 (12.0–27.0) 0.08
STS, median (IQR) [%] 12.0 (5.0–24.0) 11.0 (5.0–25.0) 14.0 (6.0–22.0) 0.65
TG max, median (IQR) [mm Hg] 87.0 (71.5–108.0) 90.0 (73.0–114.0) 82.0 (71.0–97.0) 0.13
TG mean, median (IQR) [mm Hg] 51.0 (42.5–66.5) 53.0 (43.0–69.5) 50.0 (41.0–55.0) 0.19
AVA, median (IQR) [cm2] 0.6 (0.4–0.8) 0.6 (0.5–0.8) 0.7 (0.6–0.9) 0.013
LVEF, median (IQR) [%] 60.0 (47.5–65.0) 65.0 (55.0–65.0) 50.0 (40.0–60.0) < 0.001
AVA – aortic valve area, CABG – coronary artery bypass graft, COPD – chronic obstructive pulmonary disease, CTO – chronic total occlusion, eGFR – estimated glo-
merular filtration rate, LVEF – left ventricle ejection fraction, NYHA – New York Heart Association, PCI – percutaneous coronary intervention, STS – Society of Thoracic 
Surgeons, TG – transvalvular gradient, TIA – transient ischemic attack.
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outcomes after TAVI related to gender. No differences in 
frailty or QoL assessment were observed between women 
and men. These findings with no sex-related benefit in 
terms of survival are opposite to most recent studies and 
meta-analyses reporting the protective effect of female 
gender in TAVI patients. For example, results from the 
PARTNER trial suggested lower mortality at 24 months in 
women than in men [19]. A survival advantage for females 
after TAVI has been proved in the STS/ACC TVT Registry, 
as in this registry male sex was identified as an indepen-
dent predictor of 1-year mortality [20, 21]. Furthermore, 
the previous meta-analyses revealed that female sex 
was associated with lower short- and long-term mortal-
ity [8, 11, 12]. However, data are not uniform, as some 
of the studies suggested no advantage in survival favor-
ing women. Recent studies reported similar survival for 
female and male patients [10, 11, 16]. Finally, the largest 
pooled meta-analysis to date, including a total of 11,310 
patients, reported no differences in mortality rates at 
30 days between men and women, despite the differ-
ences in baseline risk profiles [15]. However, female sex 
was independently associated with improved survival at 
median follow-up of 387 days from the index procedure. 
These results were obtained despite a higher rate of ma-
jor vascular complications, major bleeding events, and 
stroke [15]. Another meta-analysis found greater risk of 
Table II. Procedural and follow-up data
Parameter All patients (n = 101) Women (n = 61) Men (n = 40) P-value
Transfemoral access, n (%) 78 (77.2) 49 (80.3) 29 (72.5) 0.30
Transapical access, n (%) 21 (20.8) 10 (16.4) 11 (27.5)
Transaortic access, n (%) 2 (2.0) 2 (3.3) 0 (0.0)
Medtronic CoreValve, n (%) 20 (19.8) 10 (16.4) 10 (25.0) 0.48
Edwards Sapien, n (%) 77 (76.2) 49 (80.3) 28 (70.0)
Jena, n (%) 4 (4.0) 2 (3.3) 2 (5.0)
Prosthesis size: < 0.001
23 16 (15.8) 13 (21.3) 3 (7.5)
25 2 (2.0) 0 (0.0) 2 (5.0)
26 48 (47.5) 38 (62.3) 10 (25.0)
27 1 (1.0) 0 (0.0) 1 (2.5)
29 29 (28.7) 10 (16.4) 19 (47.5)
31 5 (5.0) 0 (0.0) 5 (12.5)
Prosthesis size [mm] 26.0 (26.0–29.0) 26.0 (26.0–26.0) 29.0 (26.0–29.0) < 0.001
AR before: 0.75
0 35 (34.7) 22 (36.1) 13 (32.5)
1 51 (50.5) 31 (50.8) 20 (50.0)
2 14 (13.9) 8 (13.1) 6 (15.0)
3 1 (1.0) 0 (0.0) 1 (2.5)
AR after: 0.043
0 59 (58.4) 32 (52.5) 27 (67.5)
1 36 (35.6) 25 (41.0) 11 (27.5)
2 4 (4.0) 4 (6.6) 0 (0.0)
3 2 (2.0) 0 (0.0) 2 (5.0)
Radiation dose [mGy] 733.0 (634.0–831.5) 729.0 (654.0–823.0) 769.0 (634.0–836.5) 0.78
Contrast media load [ml] 100.0 (75.0–150.0) 100.0 (75.0–150.0) 100.0 (75.0–150.0) 0.63
Fluoroscopy time [min] 14.0 (13.0–15.5) 14.0 (13.0–16.0) 14.0 (12.5–15.0) 0.44
AR – aortic regurgitation.
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major vascular complications and major and life-threat-
ening bleeding in women [11]. Permanent pacemaker im-
plantation and stroke rate were not significantly different 
between the groups in previously published data [9, 12, 
22]. Nevertheless, some studies have also reported that 
women undergoing TAVI experience higher stroke rate in 
comparison with men [11, 15]. In our study no differences 
in bleeding complications, blood transfusions, permanent 
pacemaker implantation or stoke/TIA rates were observed 
between male and female patients. Importantly, these re-
sults were maintained after adjustment for age. However, 
the numerically higher rate of stroke/TIA in males with 
a p-value 0.06 suggested that this result could reach sta-
tistical significance with a higher number of included pa-
tients. Furthermore, this result seems to be more import-
ant when we keep in mind that stroke/TIA was identified 
as an independent factor affecting long-term survival in 
our study. New-onset AF was more often reported after 
TAVI in male patients. This finding is in line with previous-
Figure 1. Proportions of patients who report ei-
ther “some problems”/“extreme problems” for 
each category of the EQ-5D-3L at baseline and at 
12 months
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Figure 2. Kaplan-Meier curves for survival after 
transcatheter valve implantation stratified by 
gender
 Women: baseline             Men: baseline         
 Woman: 12 months         Men: 12 months
Table III. Frailty indices in women and men
Parameter Categories All patients (n = 101) Women (n = 61) Men (n = 40) P-value
5MWT [s] ≥ 6, frail 18 (17.8) 9 (14.8) 9 (22.5) 0.71
EMS [points] < 10, frail 8 (7.9) 4 (6.6) 4 (10.0) 0.85
10–13 66 (65.3) 40 (65.6) 26 (65.0)
> 13 27 (26.7) 17 (27.9) 10 (25.0)
CSHA scale
[points]
1–3 56 (55.4) 37 (60.7) 19 (47.5) 0.45
4 28 (27.7) 16 (26.2) 12 (30.0)
5, frail 3 (3.0) 1 (1.6) 2 (5.0)
6–7, frail 14 (13.9) 7 (11.5) 7 (17.5)
Katz index
[points]
< 6, frail 18 (17.8) 9 (14.8) 9 (22.5) 0.43
Grip strength
[grade]
1 weak, frail 7 (6.9) 3 (4.9) 4 (10.0) 0.56
2 mild 14 (13.9) 8 (13.1) 6 (15.0)
3 strong 80 (79.2) 50 (82.0) 30 (75.0)
ISAR scale  
[points]
≥ 2, functional decline, 
frail
53 (52.5) 30 (49.2) 23 (57.5) 0.41
5-meter walking test (5MWT): ≥ 6 s – frail, < 5 s not frail; elderly mobility scale (EMS): < 10 – high level of help with mobility and activities in daily living, 10–14 – 
borderline in terms of safe mobility and independence in activities of daily living (ADL), i.e. home with help, > 14 – independent mobility, home and no help needed; 
Canadian Study of Health and Aging (CSHA) scale: 1 – very fit for one’s age, 2 – well but less fit than people in category 1, 3 – well, with treated comorbid disease, 
4 – apparently vulnerable although not frankly dependent, 5 – mildly frail with limited dependence, 6 – moderately frail, help is needed, 7 – severely frail, completely 
dependent from others, 8 – terminally ill; Katz index: 6 – not frail, < 6 – frail; Identification of Seniors at Risk (ISAR) scale: ≥ 2 indicates person at high risk of functional 
decline, 0 or 1 indicates person at low risk.
Maciej Bagienski et al. Sex-related differences in outcomes after TAVI
238 Advances in Interventional Cardiology 2017; 13, 3 (49)
ly reported data showing that women had lower adjusted 
risk for new onset AF compared with men [23]. Previous 
data postulated a lower rate of moderate to severe aor-
tic regurgitation (AR) in women after TAVI [8, 15, 24]. In 
our study AR grade 1 and 2 after TAVI was observed more 
often in female patients, while grade 3 occurred more 
frequently in men. However, this adverse event was ob-
served only in 2 patients. Females seems to have lower 
incidence of severe AR probably because of more frequent 
undersizing in men due to larger annular sizes. Potential 
bias related to the relatively small sample size could not 
be excluded. Furthermore, aortic regurgitation after TAVI 
has been shown to be associated with increased mortal-
ity [25]. In our study AR was not found to be an indepen-
dent predictor of 12-month mortality. Several factors may 
explain the suggested improved outcomes in women with 
severe AS undergoing TAVI. Higher periprocedural risk and 
rate of comorbidities are usually reported in women. Al-
most all studies found lower left ventricle ejection fraction 
at baseline in men than women undergoing TAVI, which 
might be attributed to the above-mentioned unequal 
prevalence of comorbidities [12, 26]. Importantly, bleed-
ing complications are strongly linked to poorer outcome. 
However, most of the studies reported higher prevalence 
of bleeding complications in females. It is believed that 
this is related to smaller vessel size in women [12]. Re-
duction of sheath and valve sizes may allow for a conse-
quent decrease in vascular complications. Finally, among 
patients with AS, women adapt differently than men [15]. 
Higher levels of interstitial fibrosis in men and a  more 
rapid reversal of myocardial hypertrophy in women after 
surgical aortic valve replacement were reported [27, 28]. 
Despite mortality being used to measure the effective-
ness of treatments, QoL should be an additional target 
[5–7]. The QoL improvement is commonly considered as 
a major expectation for elderly patients’ profile after TAVI. 
The improvement in QoL after TAVI may be higher than 
observed after AVR, even with the use of less invasive sur-
gical techniques (mini thoracotomy, mini sternotomy) [7]. 
Data obtained in our study demonstrated a similar rate of 
problems with usual activities in the male group in com-
parison to the female group at 12-month follow-up, with 
no difference in QoL improvement after TAVI. This may 
suggest an equal response to TAVI in regard to symptoms 
and everyday activities in men and women [29, 30]. Frailty 
assessment has also been shown as an important factor 
of overall health status, which is combined with morbidity 
and mortality in various clinical settings [17]. In our study 
we compared baseline frailty scores and their impact on 
mortality, finding no gender-related differences affecting 
outcomes. In patients with severe AS undergoing TAVI, 
frailty assessment has become crucial for decision-mak-
ing irrespective of gender.
The most important limitation of this prospective ob-
servational study is the non-randomized design. Patients 
were allocated to TAVI after the evaluation of a multidis-
ciplinary local heart team, as suggested by current guide-
lines, although this policy still might have generated an 
unavoidable risk for bias regarding treatment selection. 
Therefore, these results can only be considered to be hy-
pothesis generating rather than causative. The relatively 
small sample size did not allow us to definitively confirm/
exclude the relationship between gender and clinical out-
comes of patients with severe AS undergoing TAVI. On 
the other hand, this study represents a  comprehensive 
analysis of consecutive patients without any exclusion 
criteria and with complete frailty, QoL and follow-up data 
available for all patients. We presented the single-cen-
tre experience of 101 consecutive patients undergoing 
TAVI. Despite all these limitations, our data reflect the 
outcome of a “real-world” population which is different 
from that selected in randomized controlled trials, and 
thus the results can be extrapolated to the general pop-
ulation. Furthermore, the patients in this registry had 
a prevalence of cardiovascular risk factors comparable to 
multiple other registries and therefore accurately reflect 
real-world practice and patient selection.
Conclusions
Despite the presence of some sex-related differences 
in baseline and procedural characteristics, the all-cause 
mortality rate was similar among women and men with 
severe AS undergoing TAVI. Improvement in QoL after 
TAVI was confirmed for both sexes. Thus, TAVI can be 
considered as an effective and safe treatment strategy in 
high-risk patients, regardless of gender.
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